Testing key genetic variants like GLP1R rs6923761 and GIPR rs1800437 reveals your receptor-pathway sensitivity, helping your prescriber anticipate whether you may reach target results faster or need a more gradual approach
Most plans follow the FDA label: BMI 30 with no comorbidity required, or BMI 27 with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, NAFLD, or osteoarthritis)
This class of drugs is currently under investigation in diabetic and non-diabetic patients with heart failure, chronic kidney disease and NAFLD
Keeps 4 days in the fridge, or freeze and reheat in the air fryer
Mistake 2: attributing transition spikes to the new dose You increase from 5 mg to 7.5 mg of tirzepatide and experience severe nausea